329 related articles for article (PubMed ID: 22090419)
21. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
[TBL] [Abstract][Full Text] [Related]
22. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
Pengjam Y; Madhyastha H; Madhyastha R; Yamaguchi Y; Nakajima Y; Maruyama M
Phytomedicine; 2016 Apr; 23(4):417-28. PubMed ID: 27002412
[TBL] [Abstract][Full Text] [Related]
23. Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.
Reuter S; Gupta SC; Phromnoi K; Aggarwal BB
Br J Pharmacol; 2012 Apr; 165(7):2127-39. PubMed ID: 21955206
[TBL] [Abstract][Full Text] [Related]
24. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
[TBL] [Abstract][Full Text] [Related]
25. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
26. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
27. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B
Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
[TBL] [Abstract][Full Text] [Related]
28. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation.
Ang ES; Yang X; Chen H; Liu Q; Zheng MH; Xu J
FEBS Lett; 2011 Sep; 585(17):2755-62. PubMed ID: 21835177
[TBL] [Abstract][Full Text] [Related]
29. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
30. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
31. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
[TBL] [Abstract][Full Text] [Related]
32. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
33. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
Chiou WF; Liao JF; Huang CY; Chen CC
Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
[TBL] [Abstract][Full Text] [Related]
34. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
35. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
Park BK; Zhang H; Zeng Q; Dai J; Keller ET; Giordano T; Gu K; Shah V; Pei L; Zarbo RJ; McCauley L; Shi S; Chen S; Wang CY
Nat Med; 2007 Jan; 13(1):62-9. PubMed ID: 17159986
[TBL] [Abstract][Full Text] [Related]
36. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
[TBL] [Abstract][Full Text] [Related]
37. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
[TBL] [Abstract][Full Text] [Related]
38. Curcumin has immunomodulatory effects on RANKL-stimulated osteoclastogenesis in vitro and titanium nanoparticle-induced bone loss in vivo.
Yang C; Zhu K; Yuan X; Zhang X; Qian Y; Cheng T
J Cell Mol Med; 2020 Jan; 24(2):1553-1567. PubMed ID: 31845532
[TBL] [Abstract][Full Text] [Related]
39. Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation.
Qin S; Ang E; Dai L; Yang X; Ye D; Chen H; Zhou L; Yang M; Teguh D; Tan R; Xu J; Tickner J; Pavlos NJ; Xu J
Int J Mol Sci; 2015 Nov; 16(11):26599-607. PubMed ID: 26556352
[TBL] [Abstract][Full Text] [Related]
40. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
